Previous reports in mantle cell lymphoma cell lines show distinct cytoskeletal dynamics, ROS generation, and disruptions of NF-κB pathways after treatment with rituximab and milatuzumab (51). This evidence concerns the gene NFKB1 and mantle cell lymphoma.